Pharming Group
PHAR
9.65
0.00
0.00%
Pharming Group
US · PHAR
#3534 by market cap
Listed 2020
9.65
0.00
0.00%
Live - 5344 symbols - heartbeat 394s ago
· 2026-10-08 09:18
Pre-market
9.53
-1.28%
After-hours
9.65
0.00%
- Market cap
- 683.01M
- P/E (TTM)i
- 68.93
- P/Bi
- 2.52
- EPSi
- 0.04
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on PHAR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.41, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +26.56% YoY
Margins
- Gross margin
- 87.90%
- Operating margin
- 5.55%
- Net margin
- 0.76%
Key ratios & quality
- Enterprise valuei
- 605.33M
- Altman Z-Scorei
- 2.41
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 154.58M | 189.39M | 212.17M | 198.87M | 205.62M | 245.32M | 297.20M | 376.13M |
| Gross profit | 129.20M | 165.46M | 188.64M | 177.73M | 188.06M | 220.10M | 261.80M | 330.63M |
| Selling & admin expenses | 46.84M | 55.88M | 65.00M | 48.13M | 68.85M | 87.50M | 99.22M | 117.44M |
| Research & development | 33.04M | 31.79M | 38.52M | 70.37M | 52.53M | 68.91M | 83.15M | 100.37M |
| Operating profit | 43.46M | 68.25M | 76.26M | 19.01M | 9.86M | -22.29M | -3.67M | 20.88M |
| Pretax profit | 980.32K | 52.30M | 44.09M | 23.08M | 14.99M | -12.01M | -8.49M | 12.85M |
| Tax | -27.61M | 11.75M | 6.35M | 7.08M | 1.31M | -1.46M | 3.35M | 10.31M |
| Net profit | 28.59M | 40.56M | 37.75M | 16.00M | 13.67M | -10.55M | -11.84M | 2.54M |
| Basic EPS | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.43 | 0.61 | 0.55 | 0.23 | 0.19 | -0.16 | -0.18 | 0.04 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 79.09M | 93.22M | 97.29M | 106.50M | 72.45M | 90.21M |
| Gross profit | 70.77M | 84.25M | 90.22M | 85.40M | 65.80M | 75.67M |
| Selling & admin expenses | 57.06M | 51.55M | 51.08M | 51.30M | 45.53M | 43.52M |
| Research & development | 21.14M | 23.70M | 23.38M | 32.10M | 25.56M | 32.26M |
| Operating profit | -7.43M | 9.00M | 15.75M | 2.00M | -5.29M | -111.00K |
| Pretax profit | -11.79M | 7.08M | 12.76M | 4.80M | -4.75M | 3.04M |
| Tax | 3.10M | 2.53M | 5.21M | -500.00K | 459.00K | 1.40M |
| Net profit | -14.89M | 4.55M | 7.55M | 5.30M | -5.21M | 1.64M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.22 | 0.07 | 0.11 | 0.07 | -0.07 | 0.02 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 132.05M | 119.44M | 263.21M | 249.44M | 277.50M | 316.34M | 278.44M | 299.47M |
| Cash & ST investments | 91.87M | 74.35M | 205.16M | 191.92M | 207.34M | 213.42M | 167.89M | 179.10M |
| Inventory | 19.81M | 16.22M | 21.16M | 27.31M | 42.33M | 56.76M | 55.72M | 64.90M |
| Total assets | 245.35M | 255.92M | 418.45M | 397.32M | 425.80M | 462.85M | 399.99M | 499.96M |
| Total current liabilities | 94.49M | 114.25M | 76.85M | 46.77M | 59.70M | 77.97M | 73.80M | 115.79M |
| Short-term debt | 40.61M | 53.31M | 4.00M | 4.30M | 5.23M | 5.44M | 7.19M | 8.71M |
| Long-term debt | 42.63M | -- | 149.73M | 139.01M | 131.62M | 136.60M | 78.15M | 92.72M |
| Total liabilities | 174,709,448.64 | 138,527,000.00 | 235,018,000.00 | 204,399,000.00 | 221,159,000.00 | 244,073,000.00 | 178,924,000.00 | 222,861,000.00 |
| Total equity | 70.64M | 117.39M | 183.44M | 192.92M | 204.64M | 218.78M | 221.06M | 277.10M |
| Retained earnings | -381.65M | -340.72M | -295.62M | -273.17M | -256.43M | -265.26M | -275.49M | -272.98M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 214.11M | 245.78M | 277.60M | 299.47M | 295.51M | 280.69M |
| Cash & ST investments | 107.27M | 126.01M | 166.17M | 179.10M | 170.18M | 158.28M |
| Inventory | 59.35M | 63.72M | 67.14M | 64.90M | 64.58M | 65.43M |
| Total assets | 403.18M | 446.26M | 473.79M | 499.96M | 489.37M | 467.98M |
| Total current liabilities | 77.54M | 87.94M | 87.91M | 115.79M | 112.35M | 93.25M |
| Short-term debt | 8.79M | 9.56M | 9.69M | 8.71M | 8.15M | 9.05M |
| Long-term debt | 83.85M | 91.27M | 93.14M | 92.72M | 93.39M | 92.40M |
| Total liabilities | 187,891,000.00 | 206,708,000.00 | 209,141,000.00 | 222,861,000.00 | 220,405,000.00 | 197,494,000.00 |
| Total equity | 215.29M | 239.55M | 264.64M | 277.10M | 268.96M | 270.49M |
| Retained earnings | -292.80M | -286.03M | -276.88M | -272.98M | -281.46M | -278.25M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 46.34M | 74.15M | 83.63M | 37.84M | 22.46M | -17.30M | -1.80M | 54.71M |
| Depreciation & amortization | 7.50M | 5.80M | 8.31M | 19.61M | 13.19M | 15.93M | 16.07M | 11.22M |
| Free cash flow | 42.03M | 48.70M | 68.33M | 21.13M | 20.48M | -18.77M | -2.59M | 53.95M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | 12.01M | 3.11M | 2.79M | -- | -- | -- | -- | -- |
| Ending cash balance | 91.87M | 74.35M | 205.16M | 191.92M | 207.34M | 61.74M | 54.94M | 145.31M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 232.00K | 11.74M | 32.03M | 10.71M | 1.95M | -9.66M |
| Depreciation & amortization | 2.58M | 2.70M | 2.73M | 3.21M | 3.12M | 3.04M |
| Free cash flow | -56.00K | 11.62M | 31.96M | 10.44M | 1.71M | -9.74M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 60.09M | 92.09M | 132.37M | 145.31M | 52.38M | 158.28M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 61.36 | 43.16 | 27.00 | 8.49 | 6.88 | -4.98 | -5.38 | 1.14 |
| ROA %i | 12.85 | 16.18 | 12.04 | 3.92 | 3.32 | -2.37 | -2.74 | 0.63 |
| ROIC %i | 29.80 | 30.36 | 17.44 | 5.76 | 5.09 | -2.24 | -2.48 | 2.53 |
| 5-year avg ROE %i | -90.08 | -74.96 | -62.96 | -47.83 | 29.43 | 15.73 | 6.02 | 1.23 |
| EBIT margin %i | 11.22 | 34.67 | 23.58 | 14.67 | 9.89 | -2.47 | 0.08 | 6.27 |
| FCF / sales %i | 27.09 | 25.94 | 32.62 | 10.62 | 9.96 | -- | -- | 14.34 |
| Current ratioi | 1.40 | 1.05 | 3.43 | 5.33 | 4.65 | 4.06 | 3.77 | 2.59 |
| Quick ratioi | 1.17 | 0.90 | 3.08 | 4.69 | 3.90 | 3.28 | 2.95 | 1.97 |
| Debt / assetsi | 34.00 | 22.74 | 38.70 | 40.71 | 39.15 | 37.06 | 28.08 | 23.16 |
| LT debt / equityi | 60.62 | 4.17 | 86.11 | 81.62 | 78.90 | 75.92 | 47.55 | 38.64 |
| Interest coveragei | 1.06 | 4.92 | 8.42 | 4.79 | 3.80 | -1.01 | 0.03 | 2.20 |
| Revenue CAGR (3Y) %i | 135.48 | 124.70 | 25.43 | 8.76 | 2.78 | 4.96 | 14.33 | 22.30 |
| Net income CAGR (3Y) %i | -- | -- | -- | -17.60 | -30.40 | -- | -- | -40.70 |
| FCF CAGR (3Y) %i | -- | -- | 20.98 | -20.49 | -25.08 | -- | -- | 38.11 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -6.72 | -3.56 | 0.16 | 1.14 | 5.12 | 3.65 |
| ROA %i | -3.34 | -1.90 | 0.09 | 0.63 | 2.77 | 2.03 |
| ROIC %i | -2.19 | -0.87 | 2.37 | 2.53 | 4.04 | 4.11 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 2.69 | 4.06 | 8.01 | 6.27 | 7.63 | 7.32 |
| FCF / sales %i | 1.58 | 8.87 | 14.55 | 14.34 | 15.08 | 9.38 |
| Current ratioi | 2.76 | 2.79 | 3.16 | 2.59 | 2.63 | 3.01 |
| Quick ratioi | 2.00 | 2.04 | 2.39 | 1.97 | 2.05 | 2.31 |
| Debt / assetsi | 29.55 | 28.76 | 27.63 | 23.16 | 23.75 | 24.21 |
| LT debt / equityi | 51.57 | 49.58 | 45.81 | 38.64 | 40.18 | 38.54 |
| Interest coveragei | 0.70 | 1.34 | 2.03 | 2.20 | 3.39 | 2.44 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- RUCONEST is the largest reported line at 80.55% of revenue, across 2 reported segments.
- The next-largest line, Joenja, is a distant second at 19.45% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
RUCONEST80.55%
Joenja19.45%
Quote time 2026-10-08 09:18:35 · For reference only, not investment advice and not tailored to your situation.